Europos Sąjunga - graikų - EMA (European Medicines Agency)

laboratorios hipra, s.a. - mycoplasma hyopneumoniae, strain 7304 (nexhyon), expressing the capsid protein of porcine circovirus type 2a, inactivated - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - Χοίροι - for the active immunisation of pigs:to reduce lung lesions associated with porcine enzootic pneumonia caused by mycoplasma hyopneumoniae. also, to reduce the incidence of these lesions (as observed in field studies). to reduce viraemia, virus load in lungs and lymphoid tissues and the duration of the viraemic period associated with diseases caused by porcine circovirus type 2 (pcv2). efficacy against pcv2 genotypes a, b and d has been demonstrated in field studies. to reduce culling rate and the loss of daily weight gain caused by mycoplasma hyopneumoniae and/or pcv2 related diseases (as observed at 6 months of age in field studies). mycoplasma hyopneumoniae: onset of immunity: 3 weeks after vaccinationduration of immunity: 23 weeks after vaccinationporcine circovirus type 2:onset of immunity: 2 weeks after vaccinationduration of immunity: 22 weeks after vaccinationin addition, a reduction in nasal and faecal shedding and the duration of nasal excretion of pcv2 was demonstrated in animals challenged at 4 weeks and at 22 weeks after vaccination.

Europos Sąjunga - graikų - EMA (European Medicines Agency)

bavarian nordic a/s - τροποποιημένη δαμαλίτιδα Αγκυρα - Βαυαριανός σκανδιναβικός (mva-bn) ιός - smallpox vaccine; monkeypox virus - Άλλα ιογενή εμβόλια, - active immunisation against smallpox, monkeypox and disease caused by vaccinia virus in adults (see sections 4. 4 και 5. Η χρήση αυτού του εμβολίου θα πρέπει να γίνεται σύμφωνα με τις επίσημες συστάσεις.

Europos Sąjunga - graikų - EMA (European Medicines Agency)

ceva santé animale - αδρανοποιημένο εμβόλιο coxiella burnetii, στέλεχος nine mile - immunologicals for bovidae, inactivated bacterial vaccines (including mycoplasma, toxoid and chlamydia) - goats; cattle - cattle: , for the active immunisation of cattle to lower the risk for non-infected animals vaccinated when non-pregnant to become shedder (5 times lower probability in comparison with animals receiving a placebo), and to reduce shedding of coxiella burnetii in these animals via milk and vaginal mucus. , onset of immunity: not established. , duration of immunity: 280 days after completion of the primary vaccination course. , goats: , for the active immunisation of goats to reduce abortion caused by coxiella burnetii and to reduce shedding of the organism via milk, vaginal mucus, faeces and placenta. , onset of immunity: not established. , duration of immunity: one year after completion of the primary vaccination course.

Europos Sąjunga - graikų - EMA (European Medicines Agency)

zoetis belgium sa - live recombinant e2 gene-deleted bovine viral diarrhoea virus containing classical swine fever virus e2 gene (cp7_e2alf) - live viral vaccines, immunologicals for suidae - Χοίροι - Για την ενεργή ανοσοποίηση των χοίρων από την ηλικία των 7 εβδομάδων έως την πρόληψη της θνησιμότητας και τη μείωση της μόλυνσης και της νόσου που προκαλείται από τον ιό της κλασικής πανώλους των χοίρων (csfv). onset of immunity: 14 days after vaccinationduration of immunity: at least 6 months after vaccinationfor active immunisation of breeding females to reduce transplacental infection caused by csfv. onset of immunity: 21 days after vaccinationduration of immunity has not been demonstrated.

Europos Sąjunga - graikų - EMA (European Medicines Agency)

novavax cz, a.s. - sars cov-2 (original) recombinant spike protein, sars-cov-2 (omicron xbb.1.5) recombinant spike protein - covid-19 virus infection - covid-19 vaccines - nuvaxovid is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 12 years of age and older. Η χρήση αυτού του εμβολίου θα πρέπει να γίνεται σύμφωνα με τις επίσημες συστάσεις. nuvaxovid xbb. 5 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 12 years of age and older. Η χρήση αυτού του εμβολίου θα πρέπει να γίνεται σύμφωνα με τις επίσημες συστάσεις.

Europos Sąjunga - graikų - EMA (European Medicines Agency)

hipra human health s.l. - sars-cov-2 virus recombinant spike (s) protein receptor binding domain (rbd) fusion heterodimer – b.1.351-b.1.1.7 strains - covid-19 virus infection - Εμβόλια - bimervax is indicated as a booster for active immunisation to prevent covid-19 in individuals 16 years of age and older who have previously received a mrna covid-19 vaccine.

Graikija - graikų - Εθνικός Οργανισμός Φαρμάκων

vianex a.e. - pneumococcal vaccines - ΕΝΕΣΙΜΟ ΔΙΑΛΥΜΑ - 0,5mlpf.syr.(1dose) - ΕΜΒΟΛΙΑ - pneumococcal vaccines

Graikija - graikų - Εθνικός Οργανισμός Φαρμάκων

vianex a.e. - meningococcal vaccines - ΚΟΝΙΣ ΚΑΙ ΔΙΑΛΥΤΗΣ ΓΙΑ ΕΝΕΣΙΜΟ ΕΝΑΙΩΡΗΜΑ - 10 mcg/0,5 ml(dose) - ΕΜΒΟΛΙΑ - meningoccocal vaccines

Graikija - graikų - Εθνικός Οργανισμός Φαρμάκων

vianex a.e. - vaccines - ΕΝΕΣΙΜΟ ΕΝΑΙΩΡΗΜΑ - ΦΑΡΜΑΚΕΥΤΙΚΟ ΠΡΟΪΟΝ

Graikija - graikų - Εθνικός Οργανισμός Φαρμάκων

glaxosmithkline aebe - pertussis vaccines - ΕΝΕΣΙΜΟ ΕΝΑΙΩΡΗΜΑ - ΕΜΒΟΛΙΑ - pertussis vaccines